RNAi Therapeutics News and Research

RSS
RNA interference (RNAi) was discovered less than a decade ago and already there are human clinical trials in progress or planned. A major advantage of RNAi versus other anti-sense based approaches for therapeutic applications is that it utilizes cellular machinery that efficiently allows targeting of complementary transcripts, often resulting in highly potent down-regulation of gene expression.
Alnylam Pharmaceuticals asks Court to dismiss MIT from any claims for monetary damages in ongoing litigation

Alnylam Pharmaceuticals asks Court to dismiss MIT from any claims for monetary damages in ongoing litigation

Alnylam Pharmaceuticals initiates ALN-RSV01 Phase IIb trial in adult lung transplant patients for RSV infection

Alnylam Pharmaceuticals initiates ALN-RSV01 Phase IIb trial in adult lung transplant patients for RSV infection

Alnylam Pharmaceuticals receives 'Notice of Allowance' from USPTO

Alnylam Pharmaceuticals receives 'Notice of Allowance' from USPTO

Silence Therapeutics strengthens patent portfolio of RNAi therapeutics in solid tumor treatment

Silence Therapeutics strengthens patent portfolio of RNAi therapeutics in solid tumor treatment

Access Pharmaceuticals initiates Cobalamin technology program for targeted delivery of siRNA therapies

Access Pharmaceuticals initiates Cobalamin technology program for targeted delivery of siRNA therapies

Global health community to be engaged in using resources of GSK and Alnylam IP Pool

Global health community to be engaged in using resources of GSK and Alnylam IP Pool

New LNP compositions that improve systemic delivery of RNAi therapeutics discovered

New LNP compositions that improve systemic delivery of RNAi therapeutics discovered

Alnylam Pharmaceuticals presents data on multiple therapeutic programs at RNAi Symposium

Alnylam Pharmaceuticals presents data on multiple therapeutic programs at RNAi Symposium

Key mechanism for systemic delivery of RNAi therapeutics using LNPs discovered

Key mechanism for systemic delivery of RNAi therapeutics using LNPs discovered

Alnylam Pharmaceuticals receives payment from Roche to initiate pre-IND studies for RNAi therapeutics

Alnylam Pharmaceuticals receives payment from Roche to initiate pre-IND studies for RNAi therapeutics

DSMB recommends Quark Pharmaceuticals to continue clinical study of QPI-1002

DSMB recommends Quark Pharmaceuticals to continue clinical study of QPI-1002

Advances in development of “lipidoid” formulations for systemic delivery of RNAi therapeutics

Advances in development of “lipidoid” formulations for systemic delivery of RNAi therapeutics

Regulus Therapeutics wins exclusive rights to modulate microRNAs

Regulus Therapeutics wins exclusive rights to modulate microRNAs

Silence Therapeutics and Intradigm merge to form RNAi

Silence Therapeutics and Intradigm merge to form RNAi

USPTO issues Notice of Allowance for U.S. patent application in the 'Crooke' patent family

USPTO issues Notice of Allowance for U.S. patent application in the 'Crooke' patent family

Regulus Therapeutics to host educational webinar about microRNA biology

Regulus Therapeutics to host educational webinar about microRNA biology

New pre-clinical data from Alnylam Pharmaceuticals' ALN-VSP program presented

New pre-clinical data from Alnylam Pharmaceuticals' ALN-VSP program presented

RXi Pharmaceuticals announces financial results for the quarter ended September 30, 2009

RXi Pharmaceuticals announces financial results for the quarter ended September 30, 2009

Cequent Pharmaceuticals proposes the first test of an orally administered RNA interference drug in humans

Cequent Pharmaceuticals proposes the first test of an orally administered RNA interference drug in humans

Update on Alnylam Pharmaceuticals' RNAi pipeline, platform, and technology

Update on Alnylam Pharmaceuticals' RNAi pipeline, platform, and technology